NCT06288204 Green Propolis Extract and Royal Jelly in Hypertensive Patients and/or With Chronic Kidney Disease
| NCT ID | NCT06288204 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidade Federal Fluminense |
| Condition | Chronic Kidney Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 153 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 153 participants in total. It began in 2024-10-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This work aims to evaluate the effects of the association of green propolis extract with royal jelly on inflammation and oxidative stress in participants with chronic kidney diseases (CKD) and Systemic arterial hypertension (SAH), in a longitudinal, randomized, double-blind, placebo-controlled clinical trial that will be carried out for 2 months.
Eligibility Criteria
Inclusion Criteria: * patients in stages 3 and 5 of CKD (GFR from 15 to 59 mL/min), * patients receiving ambulatorial nutrition treatment at least 6 months * patients on regular Hemodialysis treatment for at least 6 months * patients using one to three antihypertensive drugs Exclusion Criteria: * autoimmune and infectious diseases, * diabetes * cancer * AIDS * pregnant women * patients using catabolic drugs or antibiotics; * patients with catheter access to hemodialysis; * patients using antioxidant vitamin supplements, prebiotics, probiotics, symbiotic, * Patients on regular intake of propolis who are allergic to corn starch or report being allergic to bee stings. * patients with acute myocardial infarction (AMI) and/or cerebrovascular accident (CVA)
Contact & Investigator
Denise Mafra, PhD
PRINCIPAL INVESTIGATOR
Universidade Federal Fluminense
Frequently Asked Questions
Who can join the NCT06288204 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Chronic Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06288204 currently recruiting?
Yes, NCT06288204 is actively recruiting participants. Contact the research team at dmafra30@gmail.com for enrollment information.
Where is the NCT06288204 trial being conducted?
This trial is being conducted at Rio de Janeiro, Brazil, Rio de Janeiro, Brazil.
Who is sponsoring the NCT06288204 clinical trial?
NCT06288204 is sponsored by Universidade Federal Fluminense. The principal investigator is Denise Mafra, PhD at Universidade Federal Fluminense. The trial plans to enroll 153 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.